세계의 설하 알레르기 면역요법 시장 : 산업 분석, 규모, 점유율, 성장 및 동향 예측(2024-2033년)

Sublingual Allergy Immunotherapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 6,838,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 9,987,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,630,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 설하 알레르기 면역요법(SLIT) 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 동향, 기회, 과제 등 주요 시장 역학을 상세하게 평가하고 시장 구조에 대한 통찰력을 제공합니다. 이 조사 보고서는 2024-2033년까지 세계의 설하 알레르기 면역요법 시장 예측 성장 궤도를 개설하는 독점 데이터와 통계를 제공합니다.

주요 인사이트

• 설하 알레르기 면역요법 시장 규모(2024년) : 4억 6,870만 달러
• 예측 시장 규모(2033년) : 10억 2,000만 달러
• 세계 시장 성장률(CAGR 2024-2033년) : 9.0%

설하 알레르기 면역 요법 시장 : 조사 범위

설하 알레르기 면역요법은 설하에 알레르겐을 투여하여 특정 알레르겐에 감작시키는 것으로, 알레르기성 비염이나 알레르기성 천식 등의 알레르기 질환에 대해 비침습적인 치료법을 기재하고 있습니다. 이 시장은 알레르기 전문의, 면역 전문의, 이비인후과 전문의를 대상으로 하며, 개별 환자 프로파일에 맞는 알레르겐 추출물과 치료 요법을 폭넓게 제공합니다. 시장 성장의 원동력은 알레르기 유병률 증가, 환자 의식 증가, 치료 프로토콜의 진보에 의한 치료 효과 및 환자 컴플라이언스의 향상입니다.

시장 성장 촉진요인:

세계의 설하 알레르기 면역 요법 시장은 세계 알레르기 질환의 유병률 상승, 맞춤형 의료 접근법에 대한 수요 증가, 알레르기 면역 요법 치료를 지원하는 유리한 규제 상황 등 여러 주요 요인으로 추진 되었습니다. 알레르겐 추출물의 제형 및 투여 기술에서의 기술의 진보가 시장 확대에 더욱 기여하고 있습니다. 또한, 정밀의료 및 환자 중심 의료 모델로의 전환은 시장 진출기업에 새로운 성장 기회를 제공합니다.

시장 성장 억제요인:

유망한 성장 전망에도 불구하고, 설하 알레르기 면역 요법 시장은 상환 정책, 치료 결과의 변동, 알레르겐 추출물의 생산과 유통을 관리하는 규제의 복잡성에 관한 과제에 직면하고 있습니다. 지역에 따라서는 알레르기 면역요법에 대한 보험 적용이 한정적인 것, 치료 개시에 따른 초기 비용이 고액인 것 등이 특히 신흥국에서 시장 도입의 장벽이 되고 있습니다.

시장 기회:

설하 알레르기 면역요법 시장은 알레르겐 추출물의 표준화의 진전, 호흡기 알레르기 이외의 적응의 확대, 제1선택약으로서의 설하 면역요법의 채용 확대 등에 의해 큰 성장 기회를 가져오고 있습니다. 제약 기업, 연구 기관 및 의료 제공업체가 협력하여 새로운 알레르겐 제형 및 치료 프로토콜을 개발하는 것은 새로운 기회를 활용하고 시장 진입을 확대하는 데 필수적입니다.

이 보고서에서 다루는 주요 질문

• 설하 알레르기 면역 요법 시장의 세계 성장을 가속하는 주요 요인은 무엇인가?
• 어떤 알레르겐 유형과 치료 프로토콜이 다양한 환자 집단에서의 채용을 촉진하고 있는가?
• 기술 진보는 설하 알레르기 면역 요법 시장 경쟁 구도를 어떻게 바꾸고 있는가?
• 설하 알레르기 면역 요법 시장에 기여하는 주요 진출기업은 누구이며 시장의 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 설하 알레르기 면역요법 시장에서의 새로운 동향과 미래 전망은?

목차

제1장 주요 개요

제2장 시장 개요

• 시장 범위/ 분류
• 시장의 정의/ 범위/ 제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 부가가치 통찰

• 지역별 주요 적응증의 역학
• 제품의 채용/사용 상황 분석
• 파이프라인 평가
• 규제 시나리오
• 상환의 정세
• PESTLE 분석
• PORTER 분석
• 최신 산업거래/M&A

제5장 세계 시장 수요 분석

• 과거 시장 수량(개) 분석(2019-2023년)
• 현재와 미래 시장 규모(개) 예측(2024-2033년)
  • 전년대비 성장 동향 분석

제6장 세계 시장 - 가격 분석

• 약제별 지역별 가격 분석
• 세계 평균 가격 분석 벤치마크
• 가격 설정의 전제

제7장 세계 시장 수요(금액 또는 규모, 100만 달러) 분석

• 과거 시장 매출(100만 달러) 분석(2019-2023년)
• 현재와 미래 시장 매출(100만 달러) 예측(2024-2033년)
  • 전년대비 성장 동향 분석
  • 절대 금액 기회 분석

제8장 시장 배경

• 거시경제 요인
• 예측요인 - 관련성과 영향
• 시장 역학

제9장 의약품별 세계 시장 분석

• 소개/ 주요 조사 결과
• 과거 시장 규모(100만 달러) 동향 분석, 의약품별(2019-2023년)
• 현재와 미래 시장 규모(100만 달러)의 분석과 예측, 의약품별(2024-2033년)
  • ODACTRA
  • GRASTEK
  • RAGWITEK
  • ORALAIR
  • ACTAIR
  • 기타
• 의약품별 시장의 매력 분석

제10장 증상별 세계 시장 분석

• 소개/ 주요 조사 결과
• 과거 시장 규모(100만 달러) 동향 분석, 증상별(2019-2023년)
• 현재와 미래 시장 규모(100만 달러)의 분석과 예측, 증상별(2024-2033년)
  • 알레르기성 비염
  • 알레르기성 천식
  • 음식 알레르기
  • 아토피 피부염
  • 기타
• 증상별 시장의 매력 분석

제11장 엘러간 유형별 세계 시장 분석

• 소개/ 주요 조사 결과
• 과거 시장 규모(100만 달러) 동향 분석, 엘러간 유형별(2019-2023년)
• 현재와 미래 시장 규모(100만 달러)의 분석과 예측, 엘러간 유형별(2024-2033년)
  • 꽃가루
  • 집먼지진드기(HDM)
  • 곰팡이
  • 동물 비늘
  • 벌독
  • 바퀴벌레/곤충
  • 기타
• 엘러간 유형별 시장의 매력 분석

제12장 유통채널별 세계 시장 분석

• 소개/ 주요 조사 결과
• 과거 시장 규모(100만 달러) 동향 분석, 유통 채널별(2019-2023년)
• 현재와 미래 시장 규모(100만 달러)의 분석과 예측, 유통 채널별(2024-2033년)
  • 기관 투자가를 위한 판매
    • 정부 병원
    • 준정부 병원
    • 사립병원
  • 소매 매출
    • 소매 약국
    • 약국
    • 온라인 약국
• 유통 채널별 시장의 매력 분석

제13장 지역별 세계 시장 분석

• 소개
• 과거 시장 규모(100만 달러) 동향 분석, 지역별(2019-2023년)
• 현재와 미래 시장 규모(100만 달러)의 분석과 예측, 지역별(2024-2033년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제14장 북미 시장 분석

제15장 라틴아메리카 시장 분석

제16장 유럽 시장 분석

제17장 동아시아 시장 분석

제18장 남아시아 시장 분석

제19장 오세아니아 시장

제20장 중동 및 아프리카 시장 분석

제21장 시장 구조 분석

• 기업 Tier별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장 집중
• 시장현재분석

제22장 경쟁 분석

• 경쟁 대시보드
• 주요 진출기업에 의한 브랜딩 및 프로모션 전략
• 주요 개발 분석
• 경쟁의 상세
  • ALK Abello
  • Stallergenes Greer
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Biomay AG
  • HAL Allergy group
  • DBV Technologies
  • Merck KGaA
  • WOLWpharma

제23장 사용된 전제조건과 약어

제24장 조사 방법

JHS

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the Sublingual Allergy Immunotherapy (SLIT) market. The report provides a detailed assessment of key market dynamics, including drivers, trends, opportunities, and challenges, offering insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global Sublingual Allergy Immunotherapy market from 2024 to 2033.

Key Insights:

• Sublingual Allergy Immunotherapy Market Size (2024E): USD 468.7 Million
• Projected Market Value (2033F): USD 1020 Million
• Global Market Growth Rate (CAGR 2024 to 2033): 9.0%

Sublingual Allergy Immunotherapy Market - Report Scope:

Sublingual Allergy Immunotherapy involves the administration of allergens under the tongue to desensitize patients to specific allergens, offering a non-invasive treatment option for allergic conditions such as allergic rhinitis and allergic asthma. The market caters to allergists, immunologists, and ENT specialists, providing a range of allergen extracts and treatment regimens tailored to individual patient profiles. Market growth is driven by increasing prevalence of allergies, growing patient awareness, and advancements in treatment protocols, enhancing treatment efficacy and patient compliance.

Market Growth Drivers:

The global Sublingual Allergy Immunotherapy market is propelled by several key factors, including rising prevalence of allergic disorders worldwide, increasing demand for personalized medicine approaches, and favorable regulatory landscape supporting allergy immunotherapy treatments. Technological advancements in allergen extract formulations and administration techniques are further contributing to market expansion. Moreover, the shift towards precision medicine and patient-centric healthcare models is creating new growth opportunities for market players.

Market Restraints:

Despite promising growth prospects, the Sublingual Allergy Immunotherapy market faces challenges related to reimbursement policies, variability in treatment outcomes, and regulatory complexities governing allergen extract manufacturing and distribution. Limited insurance coverage for allergy immunotherapy treatments in some regions and high upfront costs associated with treatment initiation pose barriers to market adoption, particularly in emerging economies.

Market Opportunities:

The Sublingual Allergy Immunotherapy market presents significant growth opportunities driven by advancements in allergen extract standardization, expansion of indications beyond respiratory allergies, and increasing adoption of sublingual immunotherapy as a first-line treatment option. Collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop novel allergen formulations and treatment protocols are critical to capitalize on emerging opportunities and expand market reach.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Sublingual Allergy Immunotherapy market globally?
• Which allergen types and treatment protocols are driving adoption across different patient populations?
• How are technological advancements reshaping the competitive landscape of the Sublingual Allergy Immunotherapy market?
• Who are the key players contributing to the Sublingual Allergy Immunotherapy market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global Sublingual Allergy Immunotherapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global Sublingual Allergy Immunotherapy market, including XYZ Pharmaceuticals, ABC Biotech, and PQR Allergen Solutions, focus on innovation, clinical research, and strategic partnerships to gain a competitive edge. These companies invest in R&D to enhance allergen extract efficacy, develop novel delivery systems, and expand market presence through geographic expansion and product diversification. Collaboration with healthcare providers and patient advocacy groups facilitates market access and promotes adoption of Sublingual Allergy Immunotherapy as a preferred allergy treatment option.

Key Companies Profiled:

• ALK Abello
• Stallergenes Greer
• Allergy Therapeutics
• Aimmune Therapeutics
• Merck
• Biomay AG
• HAL Allergy Group
• DBV Technologies
• Merck KgaA
• WOLWpharma

Key Segments of SLIT Industry Research

Drug:

• Odactra
• Grastek
• Ragwitek
• Oralair
• Actair
• Others

Indication:

• Allergic Rhinitis
• Allergic Asthma
• Food Allergy
• Atopic Dermatitis
• Others

Allergen:

• Pollen
• House Dust Mites
• Mold
• Animal Dander
• Bee Venom
• Cockroaches/Insects
• Others

Distribution Channel:

• Institutional Sales
• Retail Sales

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Value Added Insights

• 4.1. Epidemiology of Key Indication, By Region
• 4.2. Product Adoption/Usage Analysis
• 4.3. Pipeline Assessment
• 4.4. Regulatory Scenario
• 4.5. Reimbursement Landscape
• 4.6. PESTLE Analysis
• 4.7. PORTER Analysis
• 4.8. Latest Industry Deals/M&A

5. Global Market Demand Analysis 2019-2023 and Forecast, 2024-2033

• 5.1. Historical Market Volume (Units) Analysis, 2019-2023
• 5.2. Current and Future Market Volume (Units) Projections, 2024-2033
  • 5.2.1. Y-o-Y Growth Trend Analysis

6. Global Market - Pricing Analysis

• 6.1. Regional Pricing Analysis By Drug
• 6.2. Global Average Pricing Analysis Benchmark
• 6.3. Pricing Assumptions

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

• 8.1. Macro-Economic Factors
  • 8.1.1. Global GDP Growth Outlook
  • 8.1.2. Global Healthcare GDP Growth Overview
  • 8.1.3. Global Geriatric Population
  • 8.1.4. Global R&D Funding and Infrastructure Investment
  • 8.1.5. Global Allergy Immunotherapy Market Overview
• 8.2. Forecast Factors - Relevance & Impact
  • 8.2.1. Rising Prevalence Asthma.
  • 8.2.2. Increasing Awareness for food allergy.
  • 8.2.3. Increasing Healthcare Spending.
  • 8.2.4. Rising focus on strengthening of immune system
  • 8.2.5. Rising geriatric population
  • 8.2.6. Rise In industrialization in regions
  • 8.2.7. Rise of population due to industrial waste
  • 8.2.8. Research and development in immunotherapeutic drugs.
• 8.3. Market Dynamics
  • 8.3.1. Drivers
  • 8.3.2. Restraints
  • 8.3.3. Opportunity Analysis

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Drug

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) and Volume (Units) and Trend Analysis and Forecast By Drug, 2024-2033
  • 9.3.1. ODACTRA
  • 9.3.2. GRASTEK
  • 9.3.3. RAGWITEK
  • 9.3.4. ORALAIR
  • 9.3.5. ACTAIR
  • 9.3.6. Others
• 9.4. Market Attractiveness Analysis By Drug

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Indication

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2033
  • 10.3.1. Allergic Rhinitis
  • 10.3.2. Allergic Asthma
  • 10.3.3. Food Allergy
  • 10.3.4. Atopic Dermatitis
  • 10.3.5. Others
• 10.4. Market Attractiveness Analysis By Indication

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Allergan Type

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Trend Analysis By Allergan Type, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Allergan Type, 2024-2033
  • 11.3.1. Pollens
  • 11.3.2. House Dust Mites (HDM)
  • 11.3.3. Mould
  • 11.3.4. Animal Dander
  • 11.3.5. Bee Venom
  • 11.3.6. Cockroaches/Insects
  • 11.3.7. Others
• 11.4. Market Attractiveness Analysis By Allergan Type

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Distribution Channel

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
  • 12.3.1. Institutional Sales
    • 12.3.1.1. Gov. Hospitals
    • 12.3.1.2. Semi-Gov. Hospitals
    • 12.3.1.3. Private Hospitals
  • 12.3.2. Retail Sales
    • 12.3.2.1. Retail Pharmacy
    • 12.3.2.2. Drug Stores
    • 12.3.2.3. Online Pharmacy
• 12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2033
  • 13.3.1. North America
  • 13.3.2. Latin America
  • 13.3.3. Europe
  • 13.3.4. East Asia
  • 13.3.5. South Asia
  • 13.3.6. Oceania
  • 13.3.7. Middle East and Africa (MEA)
• 13.4. Market Attractiveness Analysis By Region

14. North America Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. U.S.
    • 14.3.1.2. Canada
  • 14.3.2. By Drug
  • 14.3.3. By Indication
  • 14.3.4. By Allergan Type
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Indication
  • 14.4.4. By Allergan Type
  • 14.4.5. By Distribution Channel
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. U.S. Market Analysis
    • 14.8.1.1. .Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Indication
      • 14.8.1.2.3. By Allergan Type
      • 14.8.1.2.4. By Distribution Channel
  • 14.8.2. Canada Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Indication
      • 14.8.2.2.3. By Allergan Type
      • 14.8.2.2.4. By Distribution Channel

15. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Mexico
    • 15.3.1.2. Brazil
    • 15.3.1.3. Argentina
    • 15.3.1.4. Rest of Latin America
  • 15.3.2. By Drug
  • 15.3.3. By Indication
  • 15.3.4. By Allergan Type
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Indication
  • 15.4.4. By Allergan Type
  • 15.4.5. By Distribution Channel
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Market Participants - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Mexico Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Indication
      • 15.8.1.2.3. By Allergan Type
      • 15.8.1.2.4. By Distribution Channel
  • 15.8.2. Brazil Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Indication
      • 15.8.2.2.3. By Allergan Type
      • 15.8.2.2.4. By Distribution Channel
  • 15.8.3. Argentina Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Indication
      • 15.8.3.2.3. By Allergan Type
      • 15.8.3.2.4. By Distribution Channel

16. Europe Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Germany
    • 16.3.1.2. U.K.
    • 16.3.1.3. France
    • 16.3.1.4. Spain
    • 16.3.1.5. Benelux
    • 16.3.1.6. Russia
    • 16.3.1.7. Italy
    • 16.3.1.8. Rest of Europe
  • 16.3.2. By Drug
  • 16.3.3. By Indication
  • 16.3.4. By Allergan Type
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Indication
  • 16.4.4. By Allergan Type
  • 16.4.5. By Distribution Channel
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Market Participants - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Germany Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Indication
      • 16.8.1.2.3. By Allergan Type
      • 16.8.1.2.4. By Distribution Channel
  • 16.8.2. U.K. Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Indication
      • 16.8.2.2.3. By Allergan Type
      • 16.8.2.2.4. By Distribution Channel
  • 16.8.3. France Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug
      • 16.8.3.2.2. By Indication
      • 16.8.3.2.3. By Allergan Type
      • 16.8.3.2.4. By Distribution Channel
  • 16.8.4. Spain Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Drug
      • 16.8.4.2.2. By Indication
      • 16.8.4.2.3. By Allergan Type
      • 16.8.4.2.4. By Distribution Channel
  • 16.8.5. BENELUX Market Analysis
    • 16.8.5.1. Introduction
    • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.5.2.1. By Drug
      • 16.8.5.2.2. By Indication
      • 16.8.5.2.3. By Allergan Type
      • 16.8.5.2.4. By Distribution Channel
  • 16.8.6. Russia Market Analysis
    • 16.8.6.1. Introduction
    • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.6.2.1. By Drug
      • 16.8.6.2.2. By Indication
      • 16.8.6.2.3. By Allergan Type
      • 16.8.6.2.4. By Distribution Channel
  • 16.8.7. Italy Market Analysis
    • 16.8.7.1. Introduction
    • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.7.2.1. By Drug
      • 16.8.7.2.2. By Indication
      • 16.8.7.2.3. By Allergan Type
      • 16.8.7.2.4. By Distribution Channel

17. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Drug
  • 17.3.3. By Indication
  • 17.3.4. By Allergan Type
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Indication
  • 17.4.4. By Allergan Type
  • 17.4.5. By Distribution Channel
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Market Participants - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug
      • 17.8.1.2.2. By Indication
      • 17.8.1.2.3. By Allergan Type
      • 17.8.1.2.4. By Distribution Channel
  • 17.8.2. Japan Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug
      • 17.8.2.2.2. By Indication
      • 17.8.2.2.3. By Allergan Type
      • 17.8.2.2.4. By Distribution Channel
  • 17.8.3. South Korea Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug
      • 17.8.3.2.2. By Indication
      • 17.8.3.2.3. By Allergan Type
      • 17.8.3.2.4. By Distribution Channel

18. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. India
    • 18.3.1.2. Indonesia
    • 18.3.1.3. Malaysia
    • 18.3.1.4. Thailand
    • 18.3.1.5. Rest of South Asia
  • 18.3.2. By Drug
  • 18.3.3. By Indication
  • 18.3.4. By Allergan Type
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug
  • 18.4.3. By Indication
  • 18.4.4. By Allergan Type
  • 18.4.5. By Distribution Channel
• 18.5. Market Trends
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Key Market Participants - Intensity Mapping
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. India Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug
      • 18.8.1.2.2. By Indication
      • 18.8.1.2.3. By Allergan Type
      • 18.8.1.2.4. By Distribution Channel
  • 18.8.2. Indonesia Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug
      • 18.8.2.2.2. By Indication
      • 18.8.2.2.3. By Allergan Type
      • 18.8.2.2.4. By Distribution Channel
  • 18.8.3. Malaysia Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.3.2.1. By Drug
      • 18.8.3.2.2. By Indication
      • 18.8.3.2.3. By Allergan Type
      • 18.8.3.2.4. By Distribution Channel
  • 18.8.4. Thailand Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.4.2.1. By Drug
      • 18.8.4.2.2. By Indication
      • 18.8.4.2.3. By Allergan Type
      • 18.8.4.2.4. By Distribution Channel

19. Oceania Market 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. Australia
    • 19.3.1.2. New Zealand
  • 19.3.2. By Drug
  • 19.3.3. By Indication
  • 19.3.4. By Allergan Type
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Drug
  • 19.4.3. By Indication
  • 19.4.4. By Allergan Type
  • 19.4.5. By Distribution Channel
• 19.5. Market Trends
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Key Market Participants - Intensity Mapping
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. Australia Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug
      • 19.8.1.2.2. By Indication
      • 19.8.1.2.3. By Allergan Type
      • 19.8.1.2.4. By Distribution Channel
  • 19.8.2. New Zealand Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug
      • 19.8.2.2.2. By Indication
      • 19.8.2.2.3. By Allergan Type
      • 19.8.2.2.4. By Distribution Channel

20. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

• 20.1. Introduction
• 20.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023
• 20.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 20.3.1. By Country
    • 20.3.1.1. GCC Countries
    • 20.3.1.2. South Africa
    • 20.3.1.3. Turkiye
    • 20.3.1.4. North Africa
    • 20.3.1.5. Rest of MEA
  • 20.3.2. By Drug
  • 20.3.3. By Indication
  • 20.3.4. By Allergan Type
  • 20.3.5. By Distribution Channel
• 20.4. Market Attractiveness Analysis
  • 20.4.1. By Country
  • 20.4.2. By Drug
  • 20.4.3. By Indication
  • 20.4.4. By Allergan Type
  • 20.4.5. By Distribution Channel
• 20.5. Market Trends
• 20.6. Drivers and Restraints - Impact Analysis
• 20.7. Key Market Participants - Intensity Mapping
• 20.8. Country Level Analysis & Forecast
  • 20.8.1. GCC Countries Market Analysis
    • 20.8.1.1. Introduction
    • 20.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.1.2.1. By Drug
      • 20.8.1.2.2. By Indication
      • 20.8.1.2.3. By Allergan Type
      • 20.8.1.2.4. By Distribution Channel
  • 20.8.2. South Africa Market Analysis
    • 20.8.2.1. Introduction
    • 20.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.2.2.1. By Drug
      • 20.8.2.2.2. By Indication
      • 20.8.2.2.3. By Allergan Type
      • 20.8.2.2.4. By Distribution Channel
  • 20.8.3. Turkiye Market Analysis
    • 20.8.3.1. Introduction
    • 20.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.3.2.1. By Drug
      • 20.8.3.2.2. By Indication
      • 20.8.3.2.3. By Allergan Type
      • 20.8.3.2.4. By Distribution Channel
  • 20.8.4. North Africa Market Analysis
    • 20.8.4.1. Introduction
    • 20.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.4.2.1. By Drug
      • 20.8.4.2.2. By Indication
      • 20.8.4.2.3. By Allergan Type
      • 20.8.4.2.4. By Distribution Channel

21. Market Structure Analysis

• 21.1. Market Analysis by Tier of Companies
• 21.2. Market Share Analysis of Top Players
• 21.3. Market Concentration
• 21.4. Market Presence Analysis

22. Competition Analysis

• 22.1. Competition Dashboard
• 22.2. Branding and Promotional Strategies, By Key Players
• 22.3. Key Development Analysis
• 22.4. Competition Deep Dive
  • 22.4.1. ALK Abello
    • 22.4.1.1. Overview
    • 22.4.1.2. Product Portfolio
    • 22.4.1.3. Key Financials
    • 22.4.1.4. Sales Footprint
    • 22.4.1.5. SWOT Analysis
    • 22.4.1.6. Strategy Overview
      • 22.4.1.6.1. Marketing Strategy
      • 22.4.1.6.2. Product Strategy
      • 22.4.1.6.3. Channel Strategy
  • 22.4.2. Stallergenes Greer
    • 22.4.2.1. Overview
    • 22.4.2.2. Product Portfolio
    • 22.4.2.3. Key Financials
    • 22.4.2.4. Sales Footprint
    • 22.4.2.5. SWOT Analysis
    • 22.4.2.6. Strategy Overview
      • 22.4.2.6.1. Marketing Strategy
      • 22.4.2.6.2. Product Strategy
      • 22.4.2.6.3. Channel Strategy
  • 22.4.3. Allergy Therapeutics
    • 22.4.3.1. Overview
    • 22.4.3.2. Product Portfolio
    • 22.4.3.3. Key Financials
    • 22.4.3.4. Sales Footprint
    • 22.4.3.5. SWOT Analysis
    • 22.4.3.6. Strategy Overview
      • 22.4.3.6.1. Marketing Strategy
      • 22.4.3.6.2. Product Strategy
      • 22.4.3.6.3. Channel Strategy
  • 22.4.4. Aimmune Therapeutics
    • 22.4.4.1. Overview
    • 22.4.4.2. Product Portfolio
    • 22.4.4.3. Key Financials
    • 22.4.4.4. Sales Footprint
    • 22.4.4.5. SWOT Analysis
    • 22.4.4.6. Strategy Overview
      • 22.4.4.6.1. Marketing Strategy
      • 22.4.4.6.2. Product Strategy
      • 22.4.4.6.3. Channel Strategy
  • 22.4.5. Biomay AG
    • 22.4.5.1. Overview
    • 22.4.5.2. Product Portfolio
    • 22.4.5.3. Key Financials
    • 22.4.5.4. Sales Footprint
    • 22.4.5.5. SWOT Analysis
    • 22.4.5.6. Strategy Overview
      • 22.4.5.6.1. Marketing Strategy
      • 22.4.5.6.2. Product Strategy
      • 22.4.5.6.3. Channel Strategy
  • 22.4.6. HAL Allergy group
    • 22.4.6.1. Overview
    • 22.4.6.2. Product Portfolio
    • 22.4.6.3. Key Financials
    • 22.4.6.4. Sales Footprint
    • 22.4.6.5. SWOT Analysis
    • 22.4.6.6. Strategy Overview
      • 22.4.6.6.1. Marketing Strategy
      • 22.4.6.6.2. Product Strategy
      • 22.4.6.6.3. Channel Strategy
  • 22.4.7. DBV Technologies
    • 22.4.7.1. Overview
    • 22.4.7.2. Product Portfolio
    • 22.4.7.3. Key Financials
    • 22.4.7.4. Sales Footprint
    • 22.4.7.5. SWOT Analysis
    • 22.4.7.6. Strategy Overview
      • 22.4.7.6.1. Marketing Strategy
      • 22.4.7.6.2. Product Strategy
      • 22.4.7.6.3. Channel Strategy
  • 22.4.8. Merck KGaA
    • 22.4.8.1. Overview
    • 22.4.8.2. Product Portfolio
    • 22.4.8.3. Key Financials
    • 22.4.8.4. Sales Footprint
    • 22.4.8.5. SWOT Analysis
    • 22.4.8.6. Strategy Overview
      • 22.4.8.6.1. Marketing Strategy
      • 22.4.8.6.2. Product Strategy
      • 22.4.8.6.3. Channel Strategy
  • 22.4.9. WOLWpharma
    • 22.4.9.1. Overview
    • 22.4.9.2. Product Portfolio
    • 22.4.9.3. Key Financials
    • 22.4.9.4. Sales Footprint
    • 22.4.9.5. SWOT Analysis
    • 22.4.9.6. Strategy Overview
      • 22.4.9.6.1. Marketing Strategy
      • 22.4.9.6.2. Product Strategy
      • 22.4.9.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology

관련자료